The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, T. R.
Right arrow Articles by Graham, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, T. R.
Right arrow Articles by Graham, B. S.
The Journal of Immunology, 2003, 170: 2037-2045.
Copyright © 2003 by The American Association of Immunologists

IL-13 Is Sufficient for Respiratory Syncytial Virus G Glycoprotein-Induced Eosinophilia After Respiratory Syncytial Virus Challenge 1

Teresa R. Johnson*,{dagger}, Robert A. Parker§, Joyce E. Johnson{ddagger} and Barney S. Graham2,*,{dagger}

* Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; Departments of {dagger} Medicine and Microbiology and Immunology and {ddagger} Pathology, Vanderbilt University School of Medicine, Nashville, TN 37232; and § Department of Medicine (Biostatistics), Harvard University School of Medicine, Boston, MA 02115

Although well studied in settings of helminth infection and allergen sensitization, the combined contributions of IL-4 and IL-13 and their signaling pathways in models of viral pathogenesis have not been reported. Using a murine model of respiratory syncytial virus (RSV) infection, we evaluated the contribution of IL-13, alone and in conjunction with IL-4, during immunization with recombinant vaccinia virus expressing RSV G glycoprotein (vvGs) or with formalin-inactivated RSV (FI-RSV). We showed that both IL-4 and IL-13 activity must be inhibited to modulate G-specific responses resulting in severe RSV-induced disease. Inhibition of IL-4 or IL-13 activity alone had minimal impact on disease in vvGs-immunized mice. However, treatment of IL-4-deficient mice with IL-13Ra during vvGs immunization reduced IL-5, IL-13, and eotaxin production and pulmonary eosinophilia after RSV challenge. In contrast, FI-RSV-induced immune responses were diminished when either IL-4 or IL-13 activity was blocked. After RSV challenge, these type 2 T cell responses were also diminished in vvGs-primed IL-4R{alpha}-deficient mice. Our data suggest that secreted vvGs uses mechanisms requiring signaling through the IL-4R{alpha}-chain by either IL-4 or IL-13 for induction of eosinophilia and is the first description of the relative contributions of IL-4, IL-13, and their receptors in viral pathogenesis.




This article has been cited by other articles:


Home page
 J. Virol.Home page
J. Liu, T. J. Ruckwardt, M. Chen, T. R. Johnson, and B. S. Graham
Characterization of Respiratory Syncytial Virus M- and M2-Specific CD4 T Cells in a Murine Model
J. Virol., May 15, 2009; 83(10): 4934 - 4941.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. M. Castilow, K. L. Legge, and S. M. Varga
Cutting Edge: Eosinophils Do Not Contribute to Respiratory Syncytial Virus Vaccine-Enhanced Disease
J. Immunol., November 15, 2008; 181(10): 6692 - 6696.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
T. R. Johnson, M. E. Rothenberg, and B. S. Graham
Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein
J. Leukoc. Biol., September 1, 2008; 84(3): 748 - 759.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. M. Castilow, D. K. Meyerholz, and S. M. Varga
IL-13 Is Required for Eosinophil Entry into the Lung during Respiratory Syncytial Virus Vaccine-Enhanced Disease
J. Immunol., February 15, 2008; 180(4): 2376 - 2384.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. R. Olson and S. M. Varga
CD8 T Cells Inhibit Respiratory Syncytial Virus (RSV) Vaccine-Enhanced Disease
J. Immunol., October 15, 2007; 179(8): 5415 - 5424.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
B. N. Gomperts, L. J. Kim, S. A. Flaherty, and B. P. Hackett
IL-13 Regulates Cilia Loss and foxj1 Expression in Human Airway Epithelium
Am. J. Respir. Cell Mol. Biol., September 1, 2007; 37(3): 339 - 346.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Phipps, C. E. Lam, S. Mahalingam, M. Newhouse, R. Ramirez, H. F. Rosenberg, P. S. Foster, and K. I. Matthaei
Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus
Blood, September 1, 2007; 110(5): 1578 - 1586.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. M. Monick, L. S. Powers, I. Hassan, D. Groskreutz, T. O. Yarovinsky, C. W. Barrett, E. M. Castilow, D. Tifrea, S. M. Varga, and G. W. Hunninghake
Respiratory Syncytial Virus Synergizes with Th2 Cytokines to Induce Optimal Levels of TARC/CCL17
J. Immunol., August 1, 2007; 179(3): 1648 - 1658.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. A. Melendi, F. R. Laham, A. C. Monsalvo, J. M. Casellas, V. Israele, N. R. Polack, S. R. Kleeberger, and F. P. Polack
Cytokine Profiles in the Respiratory Tract During Primary Infection With Human Metapneumovirus, Respiratory Syncytial Virus, or Influenza Virus in Infants
Pediatrics, August 1, 2007; 120(2): e410 - e415.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
I. Martinez, L. Lombardia, B. Garcia-Barreno, O. Dominguez, and J. A. Melero
Distinct gene subsets are induced at different time points after human respiratory syncytial virus infection of A549 cells
J. Gen. Virol., February 1, 2007; 88(2): 570 - 581.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. Bukreyev, M. E. Serra, F. R. Laham, G. A. Melendi, S. R. Kleeberger, P. L. Collins, and F. P. Polack
The Cysteine-Rich Region and Secreted Form of the Attachment G Glycoprotein of Respiratory Syncytial Virus Enhance the Cytotoxic T-Lymphocyte Response despite Lacking Major Histocompatibility Complex Class I-Restricted Epitopes.
J. Virol., June 1, 2006; 80(12): 5854 - 5861.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
R. S. Peebles Jr. and B. S. Graham
Pathogenesis of Respiratory Syncytial Virus Infection in the Murine Model
Proceedings of the ATS, August 1, 2005; 2(2): 110 - 115.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. P. Polack, P. M. Irusta, S. J. Hoffman, M. P. Schiatti, G. A. Melendi, M. F. Delgado, F. R. Laham, B. Thumar, R. M. Hendry, J. A. Melero, et al.
The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin
PNAS, June 21, 2005; 102(25): 8996 - 9001.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Huang and R. Anderson
Modulation of Protective Immunity, Eosinophilia, and Cytokine Responses by Selective Mutagenesis of a Recombinant G Protein Vaccine against Respiratory Syncytial Virus
J. Virol., April 1, 2005; 79(7): 4527 - 4532.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S.-Z. Wang, Y.-X. Bao, C. L. Rosenberger, Y. Tesfaigzi, J. M. Stark, and K. S. Harrod
IL-12p40 and IL-18 Modulate Inflammatory and Immune Responses to Respiratory Syncytial Virus Infection
J. Immunol., September 15, 2004; 173(6): 4040 - 4049.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. B. Elliott, K. S. Pryharski, Q. Yu, L. A. Boutilier, N. Campeol, K. Melville, T. S. Laughlin, C. K. Gupta, R. A. Lerch, V. B. Randolph, et al.
Characterization of Recombinant Respiratory Syncytial Viruses with the Region Responsible for Type 2 T-Cell Responses and Pulmonary Eosinophilia Deleted from the Attachment (G) Protein
J. Virol., August 15, 2004; 78(16): 8446 - 8454.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. R. Johnson, S. M. Varga, T. J. Braciale, and B. S. Graham
V{beta}14+ T Cells Mediate the Vaccine-Enhanced Disease Induced by Immunization with Respiratory Syncytial Virus (RSV) G Glycoprotein but Not with Formalin-Inactivated RSV
J. Virol., August 15, 2004; 78(16): 8753 - 8760.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. R. Johnson, M. N. Teng, P. L. Collins, and B. S. Graham
Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV
J. Virol., June 1, 2004; 78(11): 6024 - 6032.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. F. G. Antonis, R. S. Schrijver, F. Daus, P. J. G. M. Steverink, N. Stockhofe, E. J. Hensen, J. P. M. Langedijk, and R. G. van der Most
Vaccine-Induced Immunopathology during Bovine Respiratory Syncytial Virus Infection: Exploring the Parameters of Pathogenesis
J. Virol., November 15, 2003; 77(22): 12067 - 12073.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.